476 related articles for article (PubMed ID: 12510800)
41. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures.
Aspenberg P; Genant HK; Johansson T; Nino AJ; See K; Krohn K; García-Hernández PA; Recknor CP; Einhorn TA; Dalsky GP; Mitlak BH; Fierlinger A; Lakshmanan MC
J Bone Miner Res; 2010 Feb; 25(2):404-14. PubMed ID: 19594305
[TBL] [Abstract][Full Text] [Related]
42. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis.
Finkelstein JS; Arnold AL
J Clin Endocrinol Metab; 1999 Apr; 84(4):1214-9. PubMed ID: 10199756
[TBL] [Abstract][Full Text] [Related]
43. Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)].
Vahle JL; Zuehlke U; Schmidt A; Westmore M; Chen P; Sato M
J Bone Miner Res; 2008 Dec; 23(12):2033-9. PubMed ID: 18684088
[TBL] [Abstract][Full Text] [Related]
44. Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma.
Arantes HP; Barros ER; Kunii I; Bilezikian JP; Lazaretti-Castro M
J Bone Miner Res; 2011 Dec; 26(12):2823-6. PubMed ID: 21997141
[TBL] [Abstract][Full Text] [Related]
45. Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study.
Matsumoto T; Shiraki M; Hagino H; Iinuma H; Nakamura T
Osteoporos Int; 2006 Oct; 17(10):1532-8. PubMed ID: 16767525
[TBL] [Abstract][Full Text] [Related]
46. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.
Finkelstein JS; Leder BZ; Burnett SM; Wyland JJ; Lee H; de la Paz AV; Gibson K; Neer RM
J Clin Endocrinol Metab; 2006 Aug; 91(8):2882-7. PubMed ID: 16684825
[TBL] [Abstract][Full Text] [Related]
47. [Therapeutic agents for disorders of bone and calcium metabolism: Weekly subcutaneous injection of teriparatide.].
Ishizuya T
Clin Calcium; 2011 Jan; 21(1):17-24. PubMed ID: 21187590
[TBL] [Abstract][Full Text] [Related]
48. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases.
Miyauchi A; Matsumoto T; Sugimoto T; Tsujimoto M; Warner MR; Nakamura T
Bone; 2010 Sep; 47(3):493-502. PubMed ID: 20580870
[TBL] [Abstract][Full Text] [Related]
49. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
Hodsman AB; Bauer DC; Dempster DW; Dian L; Hanley DA; Harris ST; Kendler DL; McClung MR; Miller PD; Olszynski WP; Orwoll E; Yuen CK
Endocr Rev; 2005 Aug; 26(5):688-703. PubMed ID: 15769903
[TBL] [Abstract][Full Text] [Related]
50. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
[TBL] [Abstract][Full Text] [Related]
51. [Daily subcutaneous injection of teriparatide : the progress and current issues].
Yano S; Sugimoto T
Clin Calcium; 2014 Jan; 24(1):35-43. PubMed ID: 24369278
[TBL] [Abstract][Full Text] [Related]
52. [Effects of parathyroid hormone (teriparatide) on bone quality in osteoporosis].
Saito M; Marumo K
Clin Calcium; 2012 Mar; 22(3):343-55. PubMed ID: 22370301
[TBL] [Abstract][Full Text] [Related]
53. [Evidence in the treatment of osteoporosis using weekly teriparatide injections].
Nakamura Y
Clin Calcium; 2012 Mar; 22(3):407-13. PubMed ID: 22370308
[TBL] [Abstract][Full Text] [Related]
54. [Severe osteoporosis treatment with teriparatide].
Sarli MA; Zanchetta MB; Rey PG; Spivacow FR
Medicina (B Aires); 2013; 73(5):428-32. PubMed ID: 24152398
[TBL] [Abstract][Full Text] [Related]
55. Teriparatide: a review.
Quattrocchi E; Kourlas H
Clin Ther; 2004 Jun; 26(6):841-54. PubMed ID: 15262455
[TBL] [Abstract][Full Text] [Related]
56. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial.
Finkelstein JS; Klibanski A; Arnold AL; Toth TL; Hornstein MD; Neer RM
JAMA; 1998 Sep 23-30; 280(12):1067-73. PubMed ID: 9757854
[TBL] [Abstract][Full Text] [Related]
57. Complicated osteoporosis in progeroid syndrome: treatment with teriparatide.
Iglesias Bolaños P; Guijarro de Armas G; Civantos Modino S; Vega Piñero B; Pavón de Paz I; Monereo Megías S
J Clin Densitom; 2012; 15(1):116-9. PubMed ID: 22154431
[TBL] [Abstract][Full Text] [Related]
58. Spotlight on teriparatide in osteoporosis.
Blick SK; Dhillon S; Keam SJ
BioDrugs; 2009; 23(3):197-9. PubMed ID: 19627171
[TBL] [Abstract][Full Text] [Related]
59. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose.
Vahle JL; Long GG; Sandusky G; Westmore M; Ma YL; Sato M
Toxicol Pathol; 2004; 32(4):426-38. PubMed ID: 15204966
[TBL] [Abstract][Full Text] [Related]
60. Safety of daily teriparatide treatment: a post hoc analysis of a Phase III study to investigate the possible association of teriparatide treatment with calcium homeostasis in patients with serum procollagen type I N-terminal propeptide elevation.
Yamamoto T; Tsujimoto M; Sowa H
Clin Interv Aging; 2015; 10():1101-9. PubMed ID: 26185429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
